1:21-cv-01782 | Novo Nordisk Inc. et al v. Teva Pharmaceuticals, Inc. et al | Dec 21, 2021 |
1:22-cv-00294 | Novo Nordisk Inc. et al v. Rio Biopharmaceuticals, Inc. et al | Mar 4, 2022 |
1:22-cv-00295 | Novo Nordisk Inc. et al v. Aurobindo Pharma USA, Inc. et al | Mar 4, 2022 |
1:22-cv-00296 | Novo Nordisk A/S et al v. Sun Pharmaceutical Industries Ltd. et al | Mar 4, 2022 |
1:22-cv-00299 | Novo Nordisk Inc. et al v. Alvogen, Inc. | Mar 4, 2022 |
1:22-cv-00297 | Novo Nordisk Inc. et al v. Zydus Worldwide DMCC et al | Mar 4, 2022 |
1:22-cv-00023 | Novo Nordisk, Inc. et al v. Mylan Pharmaceuticals, Inc. | Mar 18, 2022 |
1:22-cv-00856 | Novo Nordisk Inc. et al v. Orbicular Pharmaceutical Technologies Pvt. Ltd., et al., | Jun 24, 2022 |
1:22-cv-00896 | Novo Nordisk Inc. et al v. Sun Pharmaceutical Industries Ltd. et al | Jul 1, 2022 |
1:22-cv-00937 | Novo Nordisk Inc. et al v. Biocon Pharma Ltd. et al | Jul 14, 2022 |
1:22-md-03038 | In Re: Ozempic (Semaglutide) Patent Litigation | Aug 5, 2022 |
1:22-cv-01040 | Novo Nordisk, Inc. et al v. Mylan Pharmaceuticals, Inc. | Aug 8, 2022 |
1:23-cv-00101 | Novo Nordisk Inc. et al v. Viatris Inc. et al | Jan 27, 2023 |
1:23-cv-00013 | Novo Nordisk, Inc. et al v. Viatris Inc. et al | Jan 27, 2023 |
IPR2023-00723 | Mylan Pharmaceuticals Inc. et al. v. Novo Nordisk A/S | Mar 16, 2023 |
IPR2023-00724 | Mylan Pharmaceuticals Inc. et al. v. Novo Nordisk A/S | Mar 16, 2023 |
2:23-cv-04031 | NOVO NORDISK INC. et al v. LUPIN LTD. | Jul 27, 2023 |
IPR2024-00009 | DR. REDDY'S LABORATORIES, INC. et al. v. Novo Nordisk A/S | Oct 20, 2023 |
IPR2024-00107 | Sun Pharmaceutical Industries Ltd. et al. v. Novo Nordisk A/S | Nov 2, 2023 |
IPR2024-00631 | Apotex Inc. et al. v. Novo Nordisk A/S | Mar 1, 2024 |